In vitro interactions of itraconazole with caspofungin or terbinafine against Sporothrix globosa

Abstract

Abstract: Sporotrichosis is a common fungal infection with limited therapeutic strategies.Combination of synergistic drugs could provide new angle for treating this disease. We used the standard broth microdilution and checkerboard method to evaluate the in vitro efficacy of combining itraconazole with caspofungin or terbinafine against the yeast and mycelial phases of Sporothrix globosa. Fractional inhibitory concentration index (FICI) was used to interprete the result as following: synergistic if the FICI is ≤0.5; indifferent if the FICI is >0.5 but ≤4 and antagonistic if the FICI is >4. For yeast phase, the synergic interaction of itraconazole combined with caspofungin or terbinafine was 93.94% (31/33) and 60.61% (20/33), respectively; for mycelial phase, the synergic interaction of itraconazole combined with caspofungin or terbinafine was 96.97% (32/33) and 84.5% (20/33), respectively. Antagonism was not observed. The in vitro efficacy of combining itraconazole with caspofungin or terbinafine showed perfect synergy against S.globosa, suggesting a potential therapeutic choice for treatment of Sporotrichosis.

Key words: Sporothrix globosa, mycelial form, yeast form, caspofungin, itraconazole, terbinafine, combined drug susceptibility testing

CLC Number:

R978.5

TAN Jing-wen, LIU Wei, LIU Wei-xia, ZHANG Jin-qing, SUN Yi, WAN Zhe, LI Ruo-yu. In vitro interactions of itraconazole with caspofungin or terbinafine against Sporothrix globosa[J]. Chinese Journal of Mycology, 2013, 8(1): 20-25.

References

[1] Barros MB,de Almeida Paes R,Schubach AO. Sporothrix schenckii and Sporotrichosis[J].Clin Microbiol Rev,2011,24(4):633-654.
[2] Ramos-e-Silva M,Vasconcelos C,Carneiro S,et al.Sporotrichosis[J].Clin Dermatol,2007,25(2):181-187.
[3] de Lima Barros MB,Schubach AO,de Vasconcellos Carvalhaes de Oliveira R,et al.Treatment of cutaneous sporotrichosis with itraconazole——study of 645 patients[J].Clin Infect Dis,2011,52(12): 200-206.
[4] Gutierrez-Galhardo MC,Zancope-Oliveira RM,Monzon A,et al. Antifungal susceptibility profile in vitro of Sporothrix schenckii in two growth phases and by two methods: microdilution and E-test[J]. Mycoses, 2009, 53(3): 227-231.
[5] Mesa-Arango AC, Del Rocio Reyes-Montes M, Perez-Mejia A, et al. Phenotyping and genotyping of Sporothrix schenckii isolates according to geographic origin and clinical form of Sporotrichosis[J]. J Clin Microbiol, 2002, 40(8): 3004-3011.
[6] Marimon R, Gene J, Cano J, et al. Molecular phylogeny of Sporothrix schenckii[J]. J Clin Microbiol, 2006, 44(9): 3251-3256.
[7] 谭静文, 刘伟, 万喆, 等. 来自中国北方部分地区33株孢子丝菌菌株的表型和基因型鉴定[J]. 菌物学报, 2013, 32(2):161-167.
[8] Schechtman RC. Sporotrichosis: Part II[J]. Skinmed, 2010, 8(5): 275-280.
[9] Sterling JB, Heymann WR. Potassium iodide in dermatology: a 19th century drug for the 21st century-uses, pharmacology, adverse effects, and contraindications[J]. J Am Acad Dermatol, 2000, 43(4): 691-697.
[10] Song Y, Li SS, Zhong SX, et al. Report of 457 sporotrichosis cases from Jilin province, northeast China, a serious endemic region[J]. J Eur Acad Dermatol Venereol, 2011, doi: 10.1111/j.1468-3083.2011.04389.x.
[11] Kauffman CA, Bustamante B, Chapman SW, et al. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2007, 45(10): 1255-1265.
[12] Denning DW. Echinocandin antifungal drugs[J]. Lancet, 2003, 362(9390): 1142-1151.
[13] Kauffman CA. Clinical efficacy of new antifungal agents[J]. Curr Opin Microbiol, 2006, 9(5): 483-488.
[14] Cao C, Liu W, Li R, er al. In vitro interactions of micafungin with amphotericin B, itraconazole or fluconazole against the pathogenic phase of Penicillium marneffei[J]. J Antimicrob Chemother, 2009, 63(2): 340-342.
[15] Arikan S, Lozano-Chiu M, Paetznick V, et al. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp.[J]. Antimicrob Agents Chemother, 2002, 46(1): 245-247.
[16] Kohler LM, Soares BM, de Assis Santos D, et al. In vitro susceptibility of isolates of Sporothrix schenckii to amphotericin B, itraconazole, and terbinafine: comparison of yeast and mycelial forms[J]. Can J Microbiol, 2006, 52(9): 843-847.
[17] 王爱平, 高那, 刘伟, 等. 伊曲康唑联合特比萘芬治疗孢子丝菌病疗效及其对病原真菌体外抗菌活性研究[J]. 中国真菌学杂志, 2011, 6(1): 5-9.
[18] Kohler LM, Monteiro PC, Hahn RC, et al. In vitro susceptibilities of isolates of Sporothrix schenckii to itraconazole and terbinafine[J]. J Clin Microbiol, 2004, 42(9): 4319-4320.
[19] Marimon R, Serena C, Gene J, et al. In vitro antifungal susceptibilities of five species of Sporothrix[J]. Antimicrob Agents Chemother, 2008, 52(2): 732-734.
[20] Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts[S]. Approved standard-Third edition M27-A3. CLSI, Wayne, PA, 2008.
[21] Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi[S]. Approved standard-Second edition M38-A2. CLSI, Wayne, PA, 2008.
[22] Trilles L, Fernandez-Torres B, Dos Santos Lazera M, et al. In vitro antifungal susceptibilities of Sporothrix schenckii in two growth phases[J]. Antimicrob Agents Chemother, 2005, 49(9): 3952-3954.
[23] Ruiz-Cendoya M, Rodriguez MM, Marine M, et al. In vitro interactions of itraconazole and micafungin against clinically important filamentous fungi[J]. Int J Antimicrob Agents, 2008, 32(5): 418-420.
[24] Odds FC. Synergy, antagonism, and what the chequerboard puts between them[J]. J Antimicrob Chemother, 2003, 52(1): 1.
[25] 刘伟, 李若瑜, 陈琼, 等. 伊曲康唑间歇冲击疗法治疗甲真菌病的血清及甲中药物水平的研究[J]. 中国皮肤性病学杂志, 2000, 14(6): 365-366.
[26] Candoni A, Mestroni R, Damiani D, et al. Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies[J]. Eur J Haematol, 2005, 75(3): 227-233.
[27] Sun Y, Liu W, Wan Z, et al. Antifungal activity of antifungal drugs, as well as drug combinations against Exophiala dermatitidis[J]. Mycopathologia, 2011, 171(2): 111-117.
[28] Li H, Lu Q, Wan Z, et al. In vitro combined activity of amphotericin B, caspofungin and voriconazole against clinical isolates of Trichosporon asahii[J]. Int J Antimicrob Agents, 2010, 35(6): 550-552.
[29] Franzot SP, Casadevall A. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro[J]. Antimicrob Agents Chemother, 1997, 41(2): 331-336.
[30] Alvarado-Ramirez E, Torres-Rodriguez JM. In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods[J]. Antimicrob Agents Chemother, 2007, 51(7): 2420-2423.
[31] Oliveira DC, Lopes PG, Spader TB, et al. Antifungal susceptibilities of Sporothrix albicans,S.brasiliensis, and S.luriei of the S.schenckii complex identified in Brazil[J]. J Clin Microbiol, 2011, 49(8): 3047-3049.
[32] 刘伟, 李若瑜. 特比萘芬的体外抗真菌活性及药物动力学特征[J]. 中国新药与临床杂志, 2000, 19(7): 8-11.